Sunshine Net Invested Capital vs Current Deferred Revenue Analysis
Sunshine Biopharma financial indicator trend analysis is much more than just breaking down Sunshine Biopharma prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sunshine Biopharma is a good investment. Please check the relationship between Sunshine Biopharma Net Invested Capital and its Current Deferred Revenue accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sunshine Biopharma Warrant. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For more information on how to buy Sunshine Stock please use our How to Invest in Sunshine Biopharma guide.
Net Invested Capital vs Current Deferred Revenue
Net Invested Capital vs Current Deferred Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sunshine Biopharma Net Invested Capital account and Current Deferred Revenue. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Sunshine Biopharma's Net Invested Capital and Current Deferred Revenue is 0.55. Overlapping area represents the amount of variation of Net Invested Capital that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Sunshine Biopharma Warrant, assuming nothing else is changed. The correlation between historical values of Sunshine Biopharma's Net Invested Capital and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Invested Capital of Sunshine Biopharma Warrant are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Net Invested Capital i.e., Sunshine Biopharma's Net Invested Capital and Current Deferred Revenue go up and down completely randomly.
Correlation Coefficient | 0.55 |
| Relationship Direction | Positive |
| Relationship Strength | Weak |
Net Invested Capital
The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Most indicators from Sunshine Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sunshine Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sunshine Biopharma Warrant. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For more information on how to buy Sunshine Stock please use our How to Invest in Sunshine Biopharma guide.At this time, Sunshine Biopharma's Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to climb to about 428.6 K in 2024, despite the fact that Issuance Of Capital Stock is likely to grow to (8.6 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Other Operating Expenses | 2.7M | 13.0M | 28.9M | 30.3M | Interest Expense | 328.8K | 39.4K | 137.3K | 148.9K |
Sunshine Biopharma fundamental ratios Correlations
Click cells to compare fundamentals
Sunshine Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Sunshine Biopharma fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 98.1K | 1.0M | 2.2M | 29.2M | 27.3M | 28.7M | |
| Total Current Liabilities | 833.5K | 1.1M | 91.2K | 6.9M | 5.6M | 5.8M | |
| Total Stockholder Equity | (735.4K) | (954.8K) | 211.7K | 21.6M | 21.2M | 22.3M | |
| Net Debt | 675.1K | 923.2K | (145.2K) | (17.6M) | (15.6M) | (14.9M) | |
| Retained Earnings | (17.4M) | (20.2M) | (32.7M) | (59.4M) | (63.9M) | (60.7M) | |
| Accounts Payable | 96.9K | 62.9K | 42.9K | 2.8M | 2.6M | 2.7M | |
| Cash | 40.5K | 989.9K | 2.0M | 21.8M | 16.3M | 17.1M | |
| Cash And Short Term Investments | 40.5K | 989.9K | 2.0M | 21.8M | 16.3M | 17.1M | |
| Common Stock Shares Outstanding | 54.7K | 10.2K | 13.1K | 151.8K | 243.3K | 255.5K | |
| Liabilities And Stockholders Equity | 98.1K | 1.0M | 2.2M | 29.2M | 27.3M | 28.7M | |
| Non Current Liabilities Total | 812.5K | 949.0K | 1.9M | 685.3K | 587.8K | 480.3K | |
| Other Stockholder Equity | 16.6M | 18.8M | 32.8M | 80.8M | 84.4M | 88.6M | |
| Total Liab | 833.5K | 2.0M | 2.0M | 7.6M | 6.1M | 6.4M | |
| Total Current Assets | 65.7K | 1.0M | 2.2M | 27.3M | 24.9M | 26.1M | |
| Common Stock | 35.3K | 346.4K | 2.6K | 22.6K | 28.0K | 26.6K | |
| Short Long Term Debt Total | 715.6K | 1.9M | 1.9M | 4.3M | 657.7K | 1.0M | |
| Other Current Liab | 21.1K | 24.3K | 48.3K | 496.2K | 2.5M | 2.7M | |
| Other Current Assets | 8.8K | 10.4K | 37.2K | 283.8K | 310.6K | 326.1K | |
| Short Term Debt | 715.6K | 964.1K | 1.9M | 3.6M | 118.7K | 112.7K | |
| Property Plant And Equipment Net | 32.5K | 19.5K | 7.1K | 1.2M | 1.0M | 1.1M | |
| Non Current Assets Total | 32.5K | 19.5K | 7.1K | 1.9M | 2.5M | 2.6M | |
| Net Receivables | 430.0 | 1.9K | 7.8K | 1.9M | 2.6M | 2.7M | |
| Accumulated Other Comprehensive Income | (2.5K) | (2.9K) | (23.1K) | 161.8K | 696.1K | 730.9K | |
| Net Tangible Assets | (105.8K) | (785.4K) | (1.1M) | 111.7K | 128.4K | 134.8K | |
| Property Plant Equipment | 45.1K | 32.5K | 19.5K | 7.1K | 6.4K | 6.0K | |
| Net Invested Capital | (69.8K) | 858.3K | 2.0M | 25.3M | 21.2M | 22.3M | |
| Capital Stock | 85.3K | 446.4K | 102.6K | 23.6K | 29.0K | 27.6K | |
| Net Working Capital | (767.8K) | (25.4K) | 2.1M | 20.4M | 19.3M | 20.3M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Sunshine Biopharma is a strong investment it is important to analyze Sunshine Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sunshine Biopharma's future performance. For an informed investment choice regarding Sunshine Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sunshine Biopharma Warrant. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For more information on how to buy Sunshine Stock please use our How to Invest in Sunshine Biopharma guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for Sunshine Stock analysis
When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |
Is Sunshine Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sunshine Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.21) | Revenue Per Share 76.716 | Quarterly Revenue Growth 0.541 | Return On Assets (0.09) | Return On Equity (0.18) |
The market value of Sunshine Biopharma is measured differently than its book value, which is the value of Sunshine that is recorded on the company's balance sheet. Investors also form their own opinion of Sunshine Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sunshine Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sunshine Biopharma's market value can be influenced by many factors that don't directly affect Sunshine Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sunshine Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sunshine Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.